South Korea Approves Shire’s Adynovate to Treat Hemophilia A Patients
Shire Korea recently received approval from South Korea’s Ministry of Food and Drug Safety for Adynovate (BAX 855), a long-lasting…
Articles by Margarida Azevedo, MSc
Chris Bombardier Becomes First Hemophiliac to Climb 7 Continents’ Highest Peaks
Chris Bombardier has just made history by becoming the first person with hemophilia ever to scale the seven summits this…
Europe’s CHMP Recommends Approval of Hemlibra to Treat Hemophilia A
Europe’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion supporting the approval of…
Adynovi Receives EU Marketing Authorization for Hemophilia A Teens, Adults
Shire recently received marketing authorization from the European Commission for Adynovi [antihemophilic factor (recombinant) PEGylated], enabling access for…
Clinical Study in Ireland Aims to Improve Care for Hemophilia Patients by Using Personalized Approaches
A novel clinical study called “The Irish Personalized Approach to the Treatment of Hemophilia (iPATH)” will seek to investigate the…
New Treatment for Hemophilic Joint Disease Granted Orphan Drug Status by FDA
The U.S. Food and Drug Administration (FDA) recently granted orphan drug status to rofecoxib (TRM-201), an non-opioid investigational pain treatment…
Chris Bombardier Readies for Climb of Mount Vinson, Final of 7 Summits, with Help of Octapharma USA
Chris Bombardier, who aims to become the first person with severe hemophiliac to climb what are known as the world’s…
FDA Grants Orphan Drug Status to Gene Therapy Candidate SHP654 for Hemophilia A
The U.S. Food and Drug Administration (FDA) recently granted orphan drug status to SHP654 (BAX 888), an investigational factor…
Arizona Hemophilia Association to Host Zombie Walk 9 in Downtown Phoenix
Look out, Phoenix, there’s a whole lot of zombies heading your way. The Arizona Hemophilia Association (AHA) is teaming up once…
Catalyst’s Recombinant Factor IX Variant for Hemophilia B Wins FDA Orphan Drug Status
The U.S. Food and Drug Administration (FDA) has granted orphan drug status (ODD) to Catalyst Biosciences’ highly potent recombinant human…